Get the Stockscreener App
1.95
5.80%
-0.12
After Hours:
1.95
Gri Bio Inc stock is traded at $1.95, with a volume of 245.82K.
It is down -5.80% in the last 24 hours and up +43.38% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$2.07
Open:
$2.07
24h Volume:
245.82K
Relative Volume:
0.93
Market Cap:
$4.18M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.0364
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
+23.42%
1M Performance:
+43.38%
6M Performance:
-84.08%
1Y Performance:
-93.37%
1-Day Range:
$1.83
$2.09
1-Week Range:
$1.5301
$2.09
52-Week Range:
$1.10
$43.69
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.95 | 3.71M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
What makes GRI Bio Inc. stock price move sharplyWatchlist Winner Update - Newser
How GRI Bio Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser
Why Eli Lilly and Company stock attracts strong analyst attentionSmart Money Signals - Newser
Why GRI Bio Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - Newser
COLX(colossuscoinxt) Price TodayFast Growing Stocks - Newser
GRI Bio stock holds Buy rating at H.C. Wainwright as Phase 2a trial completes enrollment - Investing.com
New IPF Drug Shows Promise: Phase 2a Trial Hits Key Milestone With Strong Safety Profile - Stock Titan
GRI Bio's GRI-0621: A Breakthrough in IPF with Near-Term Catalysts and a Growing Market - AInvest
GRI Bio approves reverse stock split, stockholders vote in favor - MSN
GRI Bio, Inc. Reports Positive 6-Week Interim Safety Results from its Ongoing Phase 2a Study Evaluating GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis - MarketScreener
Q2 Earnings Estimate for GRI Bio Issued By HC Wainwright - Defense World
Kalkine : GRI Bio Advancing in the Nasdaq Composite Healthcare Space - Kalkine Media
GRI Bio (NASDAQ:GRI) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for GRI Bio (NASDAQ:GRI) - Defense World
GRI Bio’s (GRI) Buy Rating Reiterated at HC Wainwright - Defense World
GRI Bio (NASDAQ:GRI) Given “Buy” Rating at HC Wainwright - Defense World
GRI Bio (NASDAQ:GRI) Earns Buy Rating from HC Wainwright - Defense World
GRI Bio’s (GRI) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
# H.C. Wainwright REITERATES Buy rating on GRI Bio stock By Investing.com - Investing.com India
# H.C. Wainwright REITERATES Buy rating on GRI Bio stock - Investing.com
GRI Stock Maintains Buy Rating and $10 Price Target | GRI Stock News - GuruFocus
Ascendiant Keeps Their Buy Rating on Verb Technology Company (VERB) - The Globe and Mail
GRI Bio (NASDAQ:GRI) Price Target Cut to $34.00 by Analysts at Ascendiant Capital Markets - Defense World
GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Sto - GuruFocus
GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Stock News - GuruFocus
GRI Bio (NASDAQ:GRI) Trading Down 4% – Here’s Why - Defense World
GRI Bio expands at-the-market offering capacity By Investing.com - Investing.com Nigeria
GRI Bio Expands Share Offering Agreement - TipRanks
GRI Bio expands at-the-market offering capacity - Investing.com
GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary Fibrosis Treatment | GRI Stock News - GuruFocus
GRI Bio Reports Positive Preclinical Data For GRI-0621 - Nasdaq
GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary F - GuruFocus
GRI Bio IncPhase 2A Study Results For GRI-0621 Expected In Q2 2025 - marketscreener.com
GRI Bio reports progress in pulmonary fibrosis treatment By Investing.com - Investing.com India
GRI Bio reports progress in pulmonary fibrosis treatment - Investing.com
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results - The Manila Times
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire
GRI Bio Stock Soars Amidst Strategic Partnership and Market Optimism - timothysykes.com
GRI Bio Advances in IPF Treatment with Promising Trial Results - TipRanks
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
GRI Bio CEO Reveals Next Steps in NKT Cell Therapy Development at Virtual Investor Series - Stock Titan
GRI Bio meets interim clinical trial enrollment goal for IPF therapy - Pulmonary Fibrosis News
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - The Manila Times
GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan
GRI Bio reports positive early trial data for IPF treatment By Investing.com - Investing.com India
GRI: Q1 Financial Report Highlights and Future Prospects | GRI S - GuruFocus
GRI Bio reports positive early trial data for IPF treatment - Investing.com
GRI: Q1 Financial Report Highlights and Future Prospects | GRI Stock News - GuruFocus
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 - The Manila Times
GRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis Treatment - Nasdaq
GRI Bio, Inc. SEC 10-Q Report - TradingView
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):